Movement Alert｜Qingsong Health Rises 13.64% in Regular Trading, Multiple Catalysts Boost AI Evidence-Based Healthcare Commercialization

Market Focus06-23

On June 23, Qingsong Health rose 13.64% in regular trading, reaching HK$16.22 per share, with turnover of approximately HK$52.89 million.

On the news front, the company recently released multiple positive developments in rapid succession. Qingsong Health signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) Biological Products, with both parties leveraging the proprietary evidence-based medical AI agent ZhengYuanFang to build a rare disease intelligent screening and full-cycle health management system. Simultaneously, the company entered into a three-year strategic MOU with Basel Medical Group to jointly expand into the Southeast Asian market.

Additionally, controlling shareholder Yang Yin voluntarily extended her lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million worth of shares from the open market. These measures effectively alleviated prior market concerns over imminent lock-up expiry selling pressure, with approximately 43 million shares previously expected to become tradable by end of June representing over 20% of total share capital.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117484219?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117484219","market":"us","top_or_hot":-1,"title":"Movement Alert｜Qingsong Health Rises 13.64% in Regular Trading, Multiple Catalysts Boost AI Evidence-Based Healthcare Commercialization","media":"Market Focus","content":"<p><p>On June 23, Qingsong Health rose 13.64% in regular trading, reaching HK$16.22 per share, with turnover of approximately HK$52.89 million.</p><p>On the news front, the company recently released multiple positive developments in rapid succession. Qingsong Health signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) Biological Products, with both parties leveraging the proprietary evidence-based medical AI agent ZhengYuanFang to build a rare disease intelligent screening and full-cycle health management system. Simultaneously, the company entered into a three-year strategic MOU with Basel Medical Group to jointly expand into the Southeast Asian market.</p><p>Additionally, controlling shareholder Yang Yin voluntarily extended her lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million worth of shares from the open market. These measures effectively alleviated prior market concerns over imminent lock-up expiry selling pressure, with approximately 43 million shares previously expected to become tradable by end of June representing over 20% of total share capital.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Qingsong Health Rises 13.64% in Regular Trading, Multiple Catalysts Boost AI Evidence-Based Healthcare Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Qingsong Health Rises 13.64% in Regular Trading, Multiple Catalysts Boost AI Evidence-Based Healthcare Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Qingsong Health rose 13.64% in regular trading, reaching HK$16.22 per share, with turnover of approximately HK$52.89 million.</p><p>On the news front, the company recently released multiple positive developments in rapid succession. Qingsong Health signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) Biological Products, with both parties leveraging the proprietary evidence-based medical AI agent ZhengYuanFang to build a rare disease intelligent screening and full-cycle health management system. Simultaneously, the company entered into a three-year strategic MOU with Basel Medical Group to jointly expand into the Southeast Asian market.</p><p>Additionally, controlling shareholder Yang Yin voluntarily extended her lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million worth of shares from the open market. These measures effectively alleviated prior market concerns over imminent lock-up expiry selling pressure, with approximately 43 million shares previously expected to become tradable by end of June representing over 20% of total share capital.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02661","symbol_name":"轻松健康","start_time":0,"source_url":"","article_id":"1117484219","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117484219","pubTimestamp":1782178456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Qingsong Health rose 13.64% in regular trading, reaching HK$16.22 per share, with turnover of approximately HK$52.89 million.On the news front, the company recently released multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02661":"轻松健康"},"translate_title":"动感快讯|青松健康常规交易涨13.64%多重催化剂助推AI循证医疗商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02661":1},"content_text":"On June 23, Qingsong Health rose 13.64% in regular trading, reaching HK$16.22 per share, with turnover of approximately HK$52.89 million.On the news front, the company recently released multiple positive developments in rapid succession. Qingsong Health signed a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) Biological Products, with both parties leveraging the proprietary evidence-based medical AI agent ZhengYuanFang to build a rare disease intelligent screening and full-cycle health management system. Simultaneously, the company entered into a three-year strategic MOU with Basel Medical Group to jointly expand into the Southeast Asian market.Additionally, controlling shareholder Yang Yin voluntarily extended her lock-up period to January 1, 2027, while the board resolved to repurchase up to HK$100 million worth of shares from the open market. These measures effectively alleviated prior market concerns over imminent lock-up expiry selling pressure, with approximately 43 million shares previously expected to become tradable by end of June representing over 20% of total share capital.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117484219","isCrawlerRequest":true}